[HTML][HTML] Gemcitabine with either paclitaxel or vinorelbine vs paclitaxel or gemcitabine alone for elderly or unfit advanced non-small-cell lung cancer patients
P Comella, G Frasci, P Carnicelli, B Massidda… - British journal of …, 2004 - nature.com
The aim of this study was to assess whether a combination of gemcitabine (GEM) with either
paclitaxel (PTX) or vinorelbine (VNR) could be more effective than GEM or PTX alone in …
paclitaxel (PTX) or vinorelbine (VNR) could be more effective than GEM or PTX alone in …
Individual patient data meta-analysis of docetaxel administered once every 3 weeks compared with once every week second-line treatment of advanced non–small …
M Di Maio, F Perrone, P Chiodini, C Gallo… - Journal of clinical …, 2007 - ascopubs.org
Purpose Although several randomized trials have been performed comparing weekly
docetaxel (wD) with standard docetaxel once every 3 weeks (3wD) as second-line treatment …
docetaxel (wD) with standard docetaxel once every 3 weeks (3wD) as second-line treatment …
A retrospective analysis of outcomes by age in a three-arm phase III trial of gemcitabine in combination with carboplatin or paclitaxel vs. paclitaxel plus carboplatin for …
RH Ansari, MA Socinski, MJ Edelman, CP Belani… - Critical reviews in …, 2011 - Elsevier
PURPOSE: Sufficient data are currently unavailable to assist in defining suitable regimens
for patients≥ 70 years with advanced non-small cell lung cancer (NSCLC). METHODS …
for patients≥ 70 years with advanced non-small cell lung cancer (NSCLC). METHODS …
Randomized controlled trial comparing docetaxel (D)-cisplatin (P) combination with D alone in elderly patients (pts) with advanced non-small cell lung cancer (NSCLC …
H Tsukada, A Yokoyama, Y Nishiwaki… - Journal of Clinical …, 2007 - ascopubs.org
7629 Background: Platinum-based chemotherapy is currently recommended as the
standard approach for pts with advanced NSCLC. However prospective clinical trials …
standard approach for pts with advanced NSCLC. However prospective clinical trials …
Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non–small-cell lung cancer
PM Fidias, SR Dakhil, AP Lyss, DM Loesch… - Journal of Clinical …, 2009 - ascopubs.org
Purpose Gemcitabine plus carboplatin (GC) is active as front-line treatment for advanced
non–small-cell lung cancer (NSCLC). For patients without progression, timing of second-line …
non–small-cell lung cancer (NSCLC). For patients without progression, timing of second-line …
Phase II randomized trial of tri-weekly versus days 1 and 8 weekly docetaxel as a second-line treatment of advanced non-small cell lung cancer
CL Lai, CM Tsai, CH Chiu, GS Wang… - Japanese journal of …, 2005 - academic.oup.com
Background: For orientals, titrating doses of docetaxel (60–66 mg/m2) have shown equal
effectiveness and fewer side effects as a second-line chemotherapy for patients with …
effectiveness and fewer side effects as a second-line chemotherapy for patients with …
Gemcitabine‐based doublets versus single‐agent therapy for elderly patients with advanced nonsmall cell lung cancer: A Literature‐based Meta‐analysis
BACKGROUND: Although platinum‐based combinations are considered the best option of
care for patients with advanced nonsmall cell lung cancer (NSCLC), single‐agent therapy is …
care for patients with advanced nonsmall cell lung cancer (NSCLC), single‐agent therapy is …
Phase II trial of weekly docetaxel in second‐line therapy for nonsmall cell lung carcinoma
RC Lilenbaum, MA Schwartz, L Seigel, F Belette… - Cancer, 2001 - Wiley Online Library
BACKGROUND The authors conducted a Phase II study to evaluate the activity and toxicity
of weekly docetaxel in second‐line therapy for nonsmall cell lung carcinoma (NSCLC) …
of weekly docetaxel in second‐line therapy for nonsmall cell lung carcinoma (NSCLC) …
[HTML][HTML] Single-agent pemetrexed or sequential pemetrexed/gemcitabine as front-line treatment of advanced non-small cell lung cancer in elderly patients or patients …
C Gridelli, E Kaukel, V Gregorc, MR Migliorino… - Journal of Thoracic …, 2007 - Elsevier
Introduction: This randomized phase II trial evaluated single-agent pemetrexed or sequential
pemetrexed/gemcitabine in patients with non-small cell lung cancer (NSCLC) who were …
pemetrexed/gemcitabine in patients with non-small cell lung cancer (NSCLC) who were …
Weekly docetaxel as second line chemotherapy for advanced non-small-cell lung cancer: meta-analysis of randomized trials
E Bria, F Cuppone, M Ciccarese, C Nisticò… - Cancer treatment …, 2006 - Elsevier
BACKGROUND: Docetaxel has to be considered as the reference control arm for second
line chemotherapy for advanced NSCLC. Weekly docetaxel has been compared to standard …
line chemotherapy for advanced NSCLC. Weekly docetaxel has been compared to standard …